InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-07-10 | Lisa McClain(R-MI09) | house | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B+17.5% | $1.19B+12.9% | $1.06B+25.0% | $847.1M+13.3% | $747.6M |
| Cost of revenue | $461.2M+4.9% | $439.6M+17.0% | $375.9M+20.5% | $311.9M+14.6% | $272.2M |
| Gross profit | $942.4M+24.8% | $755.0M+10.6% | $682.6M+27.5% | $535.2M+12.6% | $475.4M |
| Research and development | $89.8M-5.3% | $94.8M+12.3% | $84.4M+6.3% | $79.4M-24.1% | $104.6M |
| Sales, general and administrative | $663.4M+15.6% | $574.0M+13.3% | $506.5M+12.6% | $449.7M+18.9% | $378.3M |
| Acquired in-process research and development | $0 | $0-100.0% | $18.2M | $0 | $0 |
| Impairment charge | $0-100.0% | $76.9M | $0 | $0 | — |
| Total operating expenses | $753.2M+1.0% | $745.7M+22.4% | $609.1M+15.1% | $529.1M+9.6% | $482.9M |
| Income from operations | $189.2M+1939.5% | $9.3M-87.4% | $73.6M+1109.3% | $6.1M | — |
| Interest and other income | $15.9M+37.0% | $11.6M+90.0% | $6.1M | — | — |
| Income before income taxes | $205.1M+882.9% | $20.9M-73.8% | $79.7M+1946.5% | $3.9M | — |
| Provision for (benefit from) income taxes | $27.4M+300.1% | $6.9M+160.7% | -$11.3M-291.8% | $5.9M | — |
| Net income | $177.7M+1168.1% | $14.0M-84.6% | $91.0M | — | — |
| Basic (in dollars per share) | $5K+1169.4% | $360-84.8% | $2K | — | — |
| Diluted (in dollars per share) | $5K+1155.6% | $360-84.5% | $2K | — | — |
| Basic (in shares) | $38.92B+0.7% | $38.63B+0.6% | $38.40B | — | — |
| Diluted (in shares) | $39.29B+0.1% | $39.27B+0.1% | $39.22B | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Boston Scientific AGM: $20B 2025 Sales, Governance Votes Pass, Special Meeting Proposals Fail
ClearBridge Select Strategy repositions portfolio with new entries and exits
Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth